Embedded Files
Michigan Medicine emphasizes research in all residencies and fellowships. Our faculty are deeply involved in research, and they welcome and support fellow immersion in their projects.
- Protected research time: Our fellows are given 18 months total of protected time to devote to research activities in the second and third years of fellowship. During the first year, each fellow is assigned a faculty mentor who helps the fellow identify a primary mentor for their fellowship research career. With guidance from our faculty mentors, most fellows "hit the ground running" at the end of first year.
- Exposure to broad types of research: Fellows have exposure to faculty with expertise in basic, translational, and clinical sciences to work and collaborate with. Additionally, we have a robust quality improvement and patient safety program and great collaborations with the School of Public Health if you are interested in Health Services Research. If Medical Education is your passion, we have programs through the Medical School, which can "teach you to teach" more effectively. The Division of Hematology/Oncology is dedicated to the growth and success of our fellows and will support and allow you to choose the best research path for you.
- Access to resources offered by the University of Michigan: The University of Michigan has abundant resources and collaborations available to broaden your training during fellowship.
- A testament from one of our former fellows: "During my fellowship, I was able to take advantage of the excellent courses offered through the University of Michigan School of Public Health, including a survey methodology course as well as a workshop in qualitative and mixed methods research. These opportunities helped me further understand specific research methodologies used in health services research and also helped me design my fellowship research projects. I would definitely recommend these courses, as well as other School of Public Health courses, to future fellows."
- Formal training opportunities in research :
- Clinical Trials Course: All fellows will participate in a Clinical Trials held at the beginning of the second year of Fellowship. This is taught by UM faculty and discusses various topics including grant writing, Phase I/II clinical trial protocols, conducting translational research, writing LOIs, conducting health services research, and other relevant topics.
- ASCO/AACR Workshop on Methods in Clinical Cancer Research: We encourage our fellow to submit an application for this ASCO sponsored workshop. Through a generous gift, we can provide funding for up to two trainees to attend per year if their application is accepted.
- "Research Success Course": A pilot course in research success which will be held for six weeks twice a year, and will be formatted as an interactive didactic course for fellows to pitch project ideas, discuss Specific Aims pages, and develop polished proposals for grant applications.
- Grant Submission Process/Writing: The Department of Internal Medicine offers a presentation on the grant submission process for Internal Medicine faculty and fellows annually.
MiCHR: The Michigan Institute for Clinical and Health Research offers workshops such as best practices in clinical research.
Rogel Cancer Center: The Rogel Cancer Center has a dedicated site for Training, Education, and Career Development (TrEC)
Fellow Scholarly Activities 2020-2023
Fellow Scholarly Activities 2020-2023
Awards
Awards
2021 - Nicole Grogan - Conquer Cancer Merit Award Recipient, ASCO Annual Meeting
2021 - Vincent Ma - Conquer Cancer Merit Award Recipient, ASCO Annual Meeting
2021 - Jason Brown - Conquer Cancer Merit Award Recipient, ASCO Annual Meeting
2022 - Nicole Grogan Fleege - Harvard Medical School Workshop on Research Methods in Supportive Oncology
2023 - Erin Kropp - ASH Research Training Award for Fellows
2023 - Roma Bhatia - 2023-2024 Cohort of the UM Medical Education Scholars Program
Grants
Grants
2020-2022 - Chris Su - NIH T32 Training Grant
2020-2022 - Arathi Mohan - NIH T32 Training Gr2020 - Charles Foucar - NIH T32 Training Grant
2020 - Nicole Grogan - Conquer Cancer-Rising Tide Foundation for Clinical Cancer Research Career Pathway Grant in Symptom Management (“A Single Center Phase 2 Trial to Evaluate Use of Cannabidiol (CBD) to Treat Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Early Stage Breast Cancer Patients”)
2021-2023 - Erin Kropp - NIH T32 Training Grant
2021-2023 - Radhika Takiar - NIH T32 Training Grant
2021-2023 - Thomas Westbrook - NIH T32 Training Grant
2021-2023 - James Yoon - NIH T32 Training Grant
Publications
Publications
Weis TM, Hough S, Reddy HG, Daignault-Newton S, Kalemkerian GP. Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy. J Oncol Pharm Pract. 2020;26(3):564-571.
Qin A, Reddy HG, Weinberg FD, Kalemkerian GP. Cyclin-dependent kinase inhibitors for the treatment of lung cancer. Expert Opin Pharmacother. 2020;21(8):941-952.
Reddy HG, Qin A, Kalemkerian GP. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors. Expert Opin Emerg Drugs. 2020;1-14.
Ma VT, Katzman CS, Palmbos PL, et al. NB-UVB phototherapy in the treatment of anti-PD-1 inhibitor induced psoriasis: A case report. Current Problems in Cancer: Case Reports, 2020.
Ma VT, Haring CT, Warrier G, Swiecicki PL. Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma. Facial Plast Surg. 2020;36(2):186-193.
Strohbehn GW, Levy K, Tsao PA, Cronin DT, Heidemann LA, Del Valle J. The 'July Effect' in supervisory residents: assessing the emotions of rising internal medicine PGY2 residents and the impact of an orientation retreat. Med Educ Online. 2020;25(1):1728168.
Tsao PA, Caram MEV. Factors to guide treatment selection for hormone sensitive metastatic prostate cancer. Cancer J 2020;26(1):76-82.
Sankar K, Gadgeel SM, Qin A. Molecular therapeutic targets in non-small cell lung cancer. Expert Rev Anticancer Ther. 2020 Aug;20(8):647-661.
Sankar K, Pettit K. Non-Pharmacologic Management of Splenomegaly for Patients with Myelofibrosis: Is There Any Role for Splenectomy or Splenic Radiation in 2020? Curr Hematol Malig Rep. 2020 Oct;15(5):391-400.
Schwartz E, Reichert Z, Van Poznak C. Pharmacologic management of metastatic bone disease. Bone. 2020 Nov 7:115735.
Strohbehn GW, Hoffman SJK, Tokaz M, Houchens N, Slavin R, Winter S, Quinn M, Ratz D, Saint S, Chopra V, Howell JD. Visual arts in the clinical clerkship: a pilot cluster-randomized, controlled trial. BMC Med Educ. 2020 Nov 30;20(1):481.
Geer MJ, Yeow RY, Hartley S. Words Matter: Reexamining Our Vernacular. J Grad Med Educ. 2021 Apr;13(2):291. doi: 10.4300/JGME-D-21-00011.1. Epub 2021 Apr 16.
Tsung I, Worden FP, Fontana RJ. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma. Oncologist. 2021 Feb;26(2):133-138.
Sankar K, Nagrath S, Ramnath N. Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches. Cancers (Basel). 2021 Mar 23;13(6):1476.
Waninger JJ, Ma VT, Journey S, Skvarce J, Chopra Z, Tezel A, Bryant AK, Mayo C, Sun Y, Sankar K, Ramnath N, Lao C, Sussman JB, Fecher L, Alva A, Green MD. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 Mar 1;4(3):e210980.
Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL; COVID-19 and Cancer Consortium. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol. 2021 Jun 17.
Chang AE, Radke MR, Zhen DB, Baker KK, Coveler AL, Wong KM, Pillarisetty VG, Reddi D, Redman MW, Swisher E, Chiorean EG. DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma. Pancreas. 2021 May-Jun 01;50(5):e50-e52.
Su CT, Okullo D, Hingtgen S, Levine DA, Goold SD. Affordable Care Act and Cancer Survivors' Financial Barriers to Care: Analysis of the National Health Interview Survey, 2009-2018. JCO Oncol Pract. 2021 Jul 13:OP2100095.
Ma VT, Su CT, Hu M, Taylor JMG, Daignault-Newton S, Kellezi O, Dahl MN, Shah MA, Erickson S, Lora J, Hamasha R, Ali A, Yancey S, Kiros L, Balicki HM, Winfield DC, Green MD, Alva AS. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Urol Oncol. 2021 Jul;39(7):437.e1-437.e9.
Yoon J, Pettit K. Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions. Expert Rev Hematol. 2021 Jul;14(7):607-619.
Kumaraswamy A, Welker Leng KR, Westbrook TC, Yates JA, Zhao SG, Evans CP, Feng FY, Morgan TM, Alumkal JJ. Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. Eur Urol. 2021 Jul;80(1):71-81.
Chu L, Kandarpa M, Robinson D, Wu Y, Talpaz M, Pettit K. Clinical Features and Outcomes of Patients with Myelofibrosis and RAS Pathway Activating Mutations at the University of Michigan. Accepted for online publication.
Grogan N, Gjeldum D, Swartz L, Verbal K, Merajver S, Friese C, Kiyota A, Heth J, Leung D, Smith S, Gabel N, Kim M, Morikawa A. IMPACT the Brain: A Team-Based Approach to Management of Metastatic Breast Cancer with Central Nervous System Metastases. Accepted for publication.
eong AY, Schwartz EB, Roman AR, McDevitt RL, Oerline MK, Henry E, Veenstra CM, Caram MEV. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy. JCO Oncol Pract. 2021 Sep 7:OP2100168. doi: 10.1200/OP.21.00168. Epub ahead of print. PMID: 34491783.
Yoon J, Pettit K. Improving Symptom Burden and Quality of Life in Patients with Myelofibrosis: Current Strategies and Future Directions. Expert Review of Hematology. 2021 Jul;14(7):607-619
Scott, A, Mohan, A, Austin, S, Amini, E, Dedinksy, R, Raupp, S, Pannecouk, B, Narla, G, Ramnath, N. Integrating Medical Genetics into Precision Oncology Practice in the Veterans Health Administration: The Time is Now. J. Oncol. Pract. 2022 Mar. Online ahead of print. PMID 35258993.
Bryant AK, Sankar K, Strohbehn GW, Elliott D, Qin A, Yentz S, Ramnath N, and Green M. Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in
stage III non-small cell lung cancer. Lung Cancer. 2021;163:35-41. PMID 34896803.
Bryant AK, Sankar K, Strohbehn GW, Zhao L, Elliott D, Daniel V, Ramnath N, and Green M. Timing of adjuvant durvalumab initiation is not associated with outcomes in stage III non-small cell
lung cancer. Int J Radiat Oncol Biol Phys. 2022;S0360-3016(22)00002-5.
Sankar K, Bryant AK, Strohbehn GW, Zhao L, Elliott D, Moghanaki D, Kelley MJ, Ramnath N and Green M. Real world outcomes versus clinical trial results of durvalumab maintenance in veterans with stage III non-small cell lung cancer. Cancers. 2022;14(3):614.
Bryant AK, Sankar K, Strohbehn GW, Zhao L, Daniel V, Elliott D, Ramnath N and Green M. Prognostic and predictive value of PD-L1 in stage III NSCLC treated with definitive chemoradiation
and durvalumab. Int J Radiat Oncol Biol Phys. 2022 Apr 18;S0360-3016(22)00248-6.
Sankar K, Ye J, Li Z, Zheng L, Song W, and Hu-Lieskovan S. The role of biomarkers in personalized immunotherapy. Biomark Res. 2022 May 18;10(1):32.
Bryant AK, Sankar K, Zhao L, Strohbehn GW, Elliott D, Moghanaki D, Kelley MJ, Ramnath N and Green M. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung
cancer. European Journal of Cancer. Manuscript in press.
Su CT, Ye JC. Emerging Therapies for Relapsed/Refractory Multiple Myeloma: CAR-T and beyond. J Hematol Oncol. 2021 Jul 23; 14(1):115. PMID 34301270.
Su CT, Veenstra CM, Patel MR. Divergent Patterns in Care Utilization and Financial Distress Between Patients with Blood Cancers and Solid Tumors. Cancers. 2022, 14(7), 1605. PMID pending.
Westbrook TC, Guan X, Rodansky E, et al. Transcriptional Profiling of Matched Patient Biopsies Clarifies Molecular Determinants of Enzalutamide-Induced Lineage Plasticity. [Accepted, Nat. Commun.]
Storck WK, May AM, Westbrook TC, et al. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity. Front Endocrinol. 2022;13:926585
Nguyen CB and Alva AS. The Future of Radiolig and Therapies in Metastatic Castrate-Resistant Prostate Cancer. Advances in Oncology. 2023; 3(1): 129-136.
https://www.advances-oncology.com/article/S2666-853X(23)00009-7/fulltext
Victoria Wytiaz, Anne Schott, Aki Morikawa, Michelle M. Kim. Clinically significant radiation necrosis following trastuzumab-deruxtecan and brain stereotactic radiosurgery: A case series in breast cancer patients. Current problems in cancer: case reports. 2023; 10: 100242. https://doi.org/10.1016/j.cpccr.2023.100242
Christopher Kobe, Charles B Nguyen, Kyle E Kumbier, Jordan Bauman, Jennifer A Burns, Phoebe A. Tsao, Jordan B Sparks, Megan V. Caram. Clinical factors associated with prescribing patterns of bone modifying agents in men with metastatic castration-resistant prostate cancer (online publication) 2023
Jamie Mills, Valerie Gunchick, Jiaqi Shi, Aaron Udager, Timothy Frankel, Vaibhav Sahai, and Mark Zalupski. Clinicogenomic analysis of rare histologic variants of pancreatic carcinoma: undifferentiated carcinomas with and without osteoclast-like giant cells. (online publication) 2023
Leah Wells, Angel Qin, John Rice, Shirish M. Gadgeel, Bryan J. Schneider, Nithya Ramnath, Lili Zhao, Gregory Kalemkerian. A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). (online publication) 2023
Victoria A Wytiaz, Nina Levin, Chiu Yi Joey Tan, Daria Stelmak, Nicholas Iannarino, Anao Zhang, Erin Ellman, Lindsey A. Herrel, Molly Moravek, Emily Byrnes Walling, Rashmi Chugh, Brad J. Zebrack. Body image disturbances in adolescent and young adult patients with cancer confronting infertility risk and fertility preservation decisions (online publication) 2023
Victoria A. Wytiaz, Wearing Your Heart Around Your Neck: Fostering Physician-Patient Relationships Through Sports. Journal of Clinical Oncology, 2023 Feb 14; doi: 10.1200/JCO.22.02529. Online ahead of print. (Please see Torie’s podcast at https://aoopodcast.libsyn.com/wearing-your-heart-around-yourneck-fostering-physician-patient-relationships-through-sports )
Jon Weiss, John Reneau, and Ryan Wilcox, PTCL, NOS: An Update on Classification, Risk-Stratification, and Treatment. Frontiers in Oncology, vol. 13, 2023 (https://www.frontiersin.org/articles/10.3389/fonc.2023.1101441/full )
Presentations
Presentations
Brown J, Daignault S, Reichert Z, Palmbos PL, Alva AS. ABLE: single-arm trial of nab-paclitaxel with ANTI-PD1 in advanced urothelial cancer. Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 520-520.
Chang AE, Zhen DB, Radke M, Baker KK, Coveler AL, Wong KM, Pillarisetty VG, Redman MW, Swisher E, Chiorean EG. Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience. ASCO GI Cancers Symposium 2020. J Clin Oncol 2020;38(suppl 4):732.
Kump, KJ, Lieberman, M, Avelar, RA, Foucar, C, et al. Precision medicine strategy to elucidate and target Bcl-2 pro-survival proteins in a wide spectrum of cancers. Presentation at the AACR conference: Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies. San Diego, CA Jan 9, 2020.
Ma VT, Daignault S, Waninger J, Fecher LA, et al. The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020).
Carter L, Sedholm R, Schwartz E, et al. Association of LRP1B pathogenic genomic alerations with favorable outcomes with immune checkpoint inhibitos across tumor types.Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3007-3007.
Grogan N, Gjeldum D, Swartz L, Verbal K, Merajver S, Friese C, Kiyota A, Heth J, Leung D, Smith S, Gabel N, Kim M, Morikawa A. Evaluating specialty referral, research involvement, and PROs in a CNS-involved metastatic breast cancer care coordination program. ASCO Quality Care Symposium, September 2021.
Grogan N, Li Y, Kidwell K, Henry NL. Ovarian function suppression in premenopausal patient with concurrent endocrine therapy use. ASCO Annual Meeting, Chicago, IL, June 2021.
Su CT, Chen L, Chen J, Parkin B, Polk A, Kandarpa M, Cole C, Campagnaro E, Vo J, Robinson D, Wu Y, Talpaz M, Yesil J, Auclair D, Bergsagel PL, Chinnaiyan A, Baladandayuthapani V, Ye JC. “Role of aneuploidy in transcriptional regulation and clinical prognosis in relapsed and/or refractory multiple myeloma (RRMM).” Presented at ASH Annual Meeting 2020
Grogan N, Wu Y, Robinson D, Rae J, Henry NL, Hayes D, Jacobs M, Milliron K, Hulswit B, Hipp L, Merajver S, Stoffel E, Chinnaiyan A, Cobain E. Use of comprehensive next-generation sequencing to identify pathogenic germline variants with therapeutic relevance in metastatic breast cancer. ASCO, Chicago, IL, June 2021.
Sankar K, Qin A, and Ramnath N. Does dose of durvalumab matter? Relationship between length of durvalumab therapy and progression-free survival in a cohort of Veterans with stage III non-small cell lung cancer. IASLC World Conference on Lung Cancer, Singapore, January 2021.
Su CT. “Healthcare utilization between blood and solid cancer survivors and implications for financial toxicity: results from the National Health Interview Survey, 2009-2018.” Presented at National Comprehensive Cancer Network (NCCN) 2021 Virtual Annual Conference (March 20, 2021)
Sankar K, Bryant AK, Green MD, and Ramnath N. Doubling of median overall survival in a nationwide cohort of Veterans with stage III non-small cell lung cancer in the durvalumab era. ASCO Annual Meeting, Chicago, IL, June 2021.
Hoffman SJK, Reddy P, et al. Characterizing advance care planning, palliative care utilization, and location of end-of-life for adult allogeneic hematopoietic stem cell transplant recipients. ASCO Annual Meeting, Chicago, IL, June 2021.
Ma VT, Sun Y, et al. Survival outcomes associated with fewer combination ipilimumab/nivolumab doses in advanced-stage melanoma. ASCO Annual Meeting, Chicago, IL, June 2021.
Su CT, Nizialek E, et al. Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts). ASCO Annual Meeting, Chicago, IL, June 2021.
Su CT, Ye JC. Emerging Therapies for Relapsed/Refractory Multiple Myeloma: CAR-T and beyond. J Hematol Oncol. 2021 Jul 23; 14(1):115. PMID 34301270.
Grogan N, Gjeldum D, Swartz L, Verbal K, Merajver S, Friese C, Kiyota A, Heth J, Leung D, Smith S, Gabel N, Kim M, Morikawa A. IMPACT the brain: improving metastatic breast cancer patient access to coordinated treatment. The Society for Neuro-Oncology Third Annual Conference on Brain Metastases, August 2021.
Grogan N, Gjeldum D, Swartz L, Verbal K, Merajver S, Friese C, Kiyota A, Heth J, Leung D, Smith S, Gabel N, Kim M, Morikawa A. Evaluating specialty referral, research involvement, and PROs in a CNS-involved metastatic breast cancer care coordination program. American Society of Clinical Oncology Quality Care Symposium, September 2021.
Jeong AY, Schwartz EB, Roman AR, McDevitt RL, Oerline MK, Henry E, Veenstra CM, Caram MEV. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy. JCO Oncol Pract. 2021 Sep 7:OP2100168. doi: 10.1200/OP.21.00168. Epub ahead of print. PMID: 34491783.
Grogan N, Henry NL. Characterizing cannabidiol use in a breast cancer population. San Antonio Breast Cancer Symposium, December 2021.
O’Connor, CM, Taylor, SE, Miller, KM, Hurst, L, Haanen, TJ, Suhan, TK, Zawacki, KP, Noto, FK, Trako, J, Mohan, A, Sangodkar, J, Zamarin, D, DiFeo, A, Narla, G. Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. Cancer Res. 2021 Dec. PMID 34921012.
Curran C, Adib E, Kazakova V, Grivas P, Diamantopoulos L, Alva A, Su C, Jain RK, Tandon A, Necchi A, Marandino L, Plastini TM, Merchan JR, Sonpavde G. Outcomes of Metastatic Urothelial Carcinoma Following Discontinuation of Enfortumab-Vedotin. Clin Genitourin Cancer. 2022 Feb;20(1):11-16. PMID: 34503934
Scott, A, Mohan, A, Austin, S, Amini, E, Dedinksy, R, Raupp, S, Pannecouk, B, Narla, G, Ramnath, N. Integrating Medical Genetics into Precision Oncology Practice in the Veterans
Health Administration: The Time is Now. J. Oncol. Pract. 2022 Mar. Online ahead of print. PMID 35258993.
Elkrief A, Hennessy C, Kuderer NM, Rubenstein SM, Wulff-Burchfield E, Rosovsky RP, Vega-Luna K, Thompson MA, Panagiotou OA, Desai A, Rivera DR, Khaki AR, Tachiki L, Lynch RC, Stratton C, Elias R, Batist G, Kasi A, Shah DP, Bakouny Z, Cabal A, Clement J, Crowell J, Dixon B, Friese CR, Fry SL, Grover P, Gulati S, Gupta S, Hwang C, Khan H, Kim SJ, Klein EJ, Labaki C, McKay RR, Nizam A, Pennell NA, Puc M, Schmidt AL, Shahrokni A, Shaya JA, Su CT, Wall S, Williams N, Wise-Draper TM, Mishra S, Grivas P, French B, Warner JL, Wildes TM, COVID-19 and Cancer Consortium. Geriatric Risk Factors for Serious COVID-19 Outcomes Among Older Adults With Cancer: A Cohort Study From the COVID-19 and Cancer Consortium. Lancet Healthy Longev. 2022;3: e143-52. DOI: 10.1016/S2666-7568(22)00009-5.
Rubenstein SM, Bhutani D, Lynch RC, Hsu CY, Shyr Y, Advani S, Mesa RA, Mishra S, Mundt DP, Shah DP, Sica RA, Stockerl-Goldstein KE, Stratton C, Weiss M, Beeghly-Fadiel A, Accordino M, Assouline SE, Awosika J, Bakouny Z, Bashir B, Berg S, Bilen MA, Castellano CA, Cogan JC, Kc D, Friese CR, Gupta S, Hausrath D, Hwang C, Johnson NA, Joshi M, Kasi A, Klein EJ, Koshkin VS, Kuderer NM, Kwon DH, Labaki C, Latif T, Lau E, Li X, Lyman GH, McKay RR, Nagaraj G, Nizam A, Nonato TK, Olszewski AJ, Polimera HV, Portuguese AJ, Puc MM, Razavi P, Rosovski R, Schmidt A, Shah SA, Shastri A, Su C, Torka P, Wise-Draper TM, Zubiri L, Warner JL, Thompson MA. Patients Recently Treated for B-Lymphoid Malignancies Show Increased Risk of Severe COVID-19: A CCC19 Registry Analysis. Blood Cancer Discov. 2022 Mar 9 (online ahead of print). PMID 35262738
Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Efficacy of Enfortumab Vedotin in Advanced Urothelial Cancer: Analysis From the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study. Cancer. 2022 Mar 15;128(6):1194-1205. PMID 34882781
Su CT, Veenstra CM, Patel MR. Divergent Patterns in Care Utilization and Financial Distress Between Patients with Blood Cancers and Solid Tumors. Cancers. 2022, 14(7), 1605. PMID pending.
Grogan N, Gjeldum D, Swartz L, Verbal K, Merajver S, Friese C, Kiyota A, Heth J, Leung D, Smith S, Gabel N, Kim M, Morikawa A. Patient Reported Function and Sympton Burden from a Study of Coordinted Multidisciplinary Care in Breast Cancer Patients with Brain Metastases. Accepted for online publication during American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2022.
Grogan N, Gjeldum D, Swartz L, Verbal K, Merajver S, Friese C, Kiyota A, Heth J, Leung D, Smith S, Gabel N, Kim M, Morikawa A. Patient Reported Function and Sympton Burden from a Study of Coordinted Multidisciplinary Care in Breast Cancer Patients with Brain Metastases. Accepted for online publication during American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2022.
Grogan N, Henry NL. Characterizing cannabidiol use in a breast cancer population. San Antonio Breast Cancer Symposium, December 2021.
Grogan N, Gjeldum D, Swartz L, Verbal K, Merajver S, Friese C, Kiyota A, Heth J, Leung D, Smith S, Gabel N, Kim M, Morikawa A. Evaluating specialty referral, research involvement, and PROs in a CNS-involved metastatic breast cancer care coordination program. American Society of Clinical Oncology Quality Care Symposium, September 2021.
Grogan N, Gjeldum D, Swartz L, Verbal K, Merajver S, Friese C, Kiyota A, Heth J, Leung D, Smith S, Gabel N, Kim M, Morikawa A. IMPACT the brain: improving metastatic breast cancer patient access to coordinated treatment. The Society for Neuro-Oncology Third Annual Conference on Brain Metastases, August 2021.
Sankar K, Qin A, Green M, Kalemkerian G, Ramnath N. Trial in progress: phase II study of bevacizumab in combination with chemoimmunotherapy and maintenance atezolizumab in patients
with extensive-stage small cell lung cancer and liver metastases. Poster to be presented at Targeted Therapies of Lung Cancer Meeting 2022; 2022 Feb 22-26.
Schwartz EB, Jeong A, Roman A, McDevitt R, Henry E, Veenstra CM, Caram MV. Associations Between Costs, Financial Assistance Mechanisms and Time on Treatment for Patients Receiving Oral Hormonal Therapies in Prostate Cancer. Poster Presentation. University of Michigan Department of Internal Medicine Annual Research Symposium, Ann Arbor, MI, May 6, 2022
Schwartz EB, Jeong A, Roman A, McDevitt R, Henry E, Veenstra CM, Caram MV. Associations between costs of oral hormonal therapies for prostate cancer, financial assistance mechanisms, and time on treatment. Poster Presentation. ASCO Quality Care Symposium; Boston, MA, Sept 24, 2021
Reynolds SB, Wilcox S, Talpaz M, Ahmed AZ. Identifying and responding to treatment failures in Erdheim Chester Disease with a focus on Histiocytic Molecular Heterogeneity. Erdheim
Chester Disease Global Alliance Scientific Meeting 2023
Irene Tsung: Clinical outcomes after utilization of PSMAA PET scans in patients with biochemical recurrent prostate cancer. 2023 GU ASCO meeting.
Sam Reynolds: Investigating the correlation between molecular diagnostics, targeted therapies and treatment outcomes in Rosai Dorfman disease: a single-institution experience. AACR meeting 2023
Luke Fraley: In It Together: Teaching a Team-Based Approach to Patient-Initiated Mistreatment oral presentation SGIM meeting 2023.
Workshops
Workshops
2019 - Amy Chang - ASCO/AACR Vail Methods in Clinical Cancer Research Workshop
2020 - Amy Chang - FDA/ASCO Fellows Day
2020 - Amy Chang - NCCN Annual Conference
2020 - Nicole Grogan - ASCO/AACR Vail Methods in Clinical Cancer Research Workshop
2020 - Kamya Sankar - Annual Young Investigators Forum in Lung Cancer
2021 - Arathi Mohan - AACR Integrative Molecular Epidemiology Workshop
2021 - Kamya Sankar - ASCO/AACR Vail Methods in Clinical Cancer Research Workshop
2022 - Marcus Geer - ASCO/AACR Vail Methods in Clinical Cancer Research Workshop
2022 - Charles Nguyen - ASCO/AACR Vail Methods in Clinical Cancer Research Workshop
2022 - Irene Tsung - ASCO/AACR Vail Methods in Clinical Cancer Research Workshop
2022 - Jonathan Weiss - ASCO/AACR Vail Methods in Clinical Cancer Research Workshop
2022 - Samuel Reynolds - AACR Molecular Biology in Clinical Oncology Workshop
Page updated
Report abuse